SVB Leerink Reiterates Outperform on Sarepta Therapeutics, Maintains $160 Price Target
SVB Leerink analyst Joseph Schwartz reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $160 price target.
Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $160
Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $158 to $160.
Sarepta Therapeutics Reports Preliminary Q4 And FY22 Net Product Revenues; Expects To Exceed FY22 Guidance For Net Product Revenues; Q4 And FY22 Are Expected To Total $235.5M And $843.3M
- The Company expects to exceed 2022 full-year guidance for net product revenues
- Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5
UBS Upgrades Sarepta Therapeutics to Buy, Raises Price Target to $158
UBS analyst Colin Bristow upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Buy and raises the price target from $100 to $158.
Sarepta Therapeutics Announces That U.S. FDA Has Accepted For Filing And Granted Priority Review For The Biologics License Application For SRP-9001, Sarepta’s Gene Therapy For The Treatment Of Ambulant Individuals With Duchenne Muscular Dystrophy
– Regulatory action date of May 29, 2023
– SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional
Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Raises Price Target to $141
Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and raises the price target from $135 to $141.
PepGen’s Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta’s Candidate, Says Analyst
PepGen Inc (NASDAQ:PEPG) reported data from PGN-EDO51’s SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes…
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Analyst Ratings for Sarepta Therapeutics
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
Sarepta Therapeutics Inc (NASDAQ:SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone…